scholarly journals Serum intact parathyroid hormone levels in cats with chronic kidney disease

2013 ◽  
Vol 33 (2) ◽  
pp. 229-235 ◽  
Author(s):  
Luciano H. Giovaninni ◽  
Marcia M. Kogika ◽  
Marcio D. Lustoza ◽  
Archivaldo Reche Junior ◽  
Vera A.B.F. Wirthl ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Stage Iv ◽  
Control Group ◽  
Intact Parathyroid Hormone ◽  
Acid Base ◽  
Acid Base Status ◽  
Serum Ionized Calcium ◽  
Progression Of Renal Disease

Chronic kidney disease (CKD) is frequently observed in cats and it is characterized as a multisystemic illness, caused by several underlying metabolic changes, and secondary renal hyperparathyroidism (SRHPT) is relatively common; usually it is associated with the progression of renal disease and poor prognosis. This study aimed at determining the frequency of SRHPT, and discussing possible mechanisms that could contribute to the development of SRHPT in cats at different stages of CKD through the evaluation of calcium and phosphorus metabolism, as well as acid-base status. Forty owned cats with CKD were included and divided into three groups, according to the stages of the disease, classified according to the International Renal Interest Society (IRIS) as Stage II (n=12), Stage III (n=22) and Stage IV (n=6). Control group was composed of 21 clinically healthy cats. Increased serum intact parathyroid hormone (iPTH) concentrations were observed in most CKD cats in all stages, and mainly in Stage IV, which hyperphosphatemia and ionized hypocalcemia were detected and associated to the cause for the development of SRHPT. In Stages II and III, however, ionized hypercalcemia was noticed suggesting that the development of SRHPT might be associated with other factors, and metabolic acidosis could be involved to the increase of serum ionized calcium. Therefore, causes for the development of SRHPT seem to be multifactorial and they must be further investigated, mainly in the early stages of CKD in cats, as hyperphosphatemia and ionized hypocalcemia could not be the only factors involved.

scholarly journals Intact Parathyroid Hormone Level in Different Stages of Chronic Kidney Disease

2011 ◽  
Vol 17 (Number 2) ◽  
pp. 9-14
Author(s):  
N Y Mili ◽  
R Begum ◽  
Md. E Hoque ◽  
Q S Akhter
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Hormone Level ◽  
Stage Iv ◽  
Control Group ◽  
Parathyroid Hormone Level ◽  
Intact Pth ◽  
Three Stages ◽  
Pth Level

Secondary hyperparathyroidism is the first and most recognizable complication of chronic kidney disease (CKD) because parathyroid hormone (PTH) plays a compensatory role to maintain calcium and phosphate homeostasis. Progressive renal failure give rise to a steady increase in parathyroid hormone concentration. which is related to occurrence of renal bone disease. The objective of this study was to find out the httact parathyroid hormone level in different stages of chronic kidney disease patients. This cross sectional study was carried ow in the department of physiology. Dhaka Medical College from January to December 2009. 100 chronic kidney disease patients aged 20 to 60 years were selected as experimental group and 20 apparently healthy subjects were in control group and were matched for age and body weight. Patients were divided into three stages based on their creatinine clearance rate (Ccr). Group B, includes 34 patients marked as stage 11 with Ccr 60-89 ml/min, Group Ba Group B3 consists of 36 and 30 patients each and marked as stage 111 and stage IV with Ccr 30-59 mIhnin and 15-29 Skills respectively. Intact PTH was measured by chemiluminescent hnutuno assay method. Statistical analysis was done by unpaired Student's "1"- test and pearson's Correlation test. Mean serum PTH level was significantly higher in all experimental groups than that of control group (p< 0.001). High level of Pal was found in 74% patients in stage 11, 81% in stage III and 97% patients in stage IV. Again, a significant negative correlation of parathyroid hormone with Ccr was observed in patients with CKD in all three stages. From the findings of the present study it may be concluded that intact PTH level progressively increases from early stage to late stage of chronic kidney disease.

Spot urinary citrate-to-creatinine ratio is a marker for acid-base status in chronic kidney disease

2021 ◽  
Vol 99 (1) ◽  
pp. 208-217 ◽  
Author(s):  
Fabiola G. Gianella ◽  
Victor E. Prado ◽  
John R. Poindexter ◽  
Beverley Adams-Huet ◽  
Xilong Li ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Creatinine Ratio ◽  
Acid Base ◽  
Acid Base Status ◽  
Urinary Citrate

scholarly journals Outcome of supplementation of vitamin D on intact parathyroid hormone level in chronic kidney disease patients

2019 ◽  
Vol 8 (2) ◽  
pp. 51-54
Author(s):  
Laxman Prasad Adhikary ◽  
Aarjan Khanal
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Hormone Level ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Intact Parathyroid Hormone ◽  
Parathyroid Hormone Level ◽  
Modifiable Factors ◽  
The Mean

Background: Secondary hyperparathyroidism is present in majority of patients with estimated glomerular filtrate rate less than 60 mL/min/1.73 m2. Sustained elevated parathyroid hormone level can cause osteitis-fibrosa-cystica, fracture, hypercalcemia, hyperphosphatemia, and calciphylaxis. Kidney Disease Improving Global Outcome guidelines for Chronic Kidney Disease Mineral and Bone Disorder 2017 recommends treatment with calcitriol or vitamin D analogue if parathyroid hormone level is progressively increasing and remains persistently above the upper limit despite correction of modifiable factors. Objectives: The objective of this study was to determine the mean change in intact parathyroid hormone aftercalcitriol supplementation in patients with chronic kidney disease (stage 3 to 5). Methodology: This prospective observational study enrolled 92 patients with chronic kidney disease stage 3 to 5, not under maintenance hemodialysis. Patients who had intact parathyroid hormone level more than 200 pg/ml, serum phosphate level less than 4.5 mg/dl and corrected serum calcium less than 9.5 mg/dl were selected for the study. They were supplemented with oral calcitriol 0.25μg thrice weekly for three months and intact parathyroid hormone level was measured after three months. Results: Mean intact parathyroid hormone level before supplementation was 332.91 ± 96.046pg/ml and after three months of supplementation with calcitriol was 176.49 ±53.764pg/ml. This finding was statistically significant (Correlation: 0.471, p-value less than 0.05). Thus, supplementation of calcitriol reduced the mean intact parathyroid hormone level in the chronic kidney disease patients in our study. Conclusion: Calcitriol supplementation seems to be an effective measure to reduce intact parathyroid hormone level in chronic kidney disease patients when it remains persistently high despite correction of modifiable factors.

Influence of Renal Function and Diet on Acid-Base Status in Chronic Kidney Disease Patients

2009 ◽  
Vol 19 (2) ◽  
pp. 178-182 ◽  
Author(s):  
Viviane O. Leal ◽  
Alvimar G. Delgado ◽  
Maurilo Leite ◽  
William E. Mitch ◽  
Denise Mafra
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Acid Base ◽  
Acid Base Status

scholarly journals Serum Intact Parathyroid Hormone Level is Inversely Correlated with Glycated Haemoglobin in Diabetic Chronic Kidney Disease Stages 3-5 Predialysis Patients

2017 ◽  
Vol 7 (2) ◽  
pp. 110-113
Author(s):  
Wasim Md Mohosin Ul Haque ◽  
Muhammad Abdur Rahim ◽  
Palash Mitra ◽  
Tabassum Samad ◽  
Samira Humaira Habib ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Negative Correlation ◽  
Glycated Haemoglobin ◽  
Diabetic Patients ◽  
Intact Parathyroid Hormone ◽  
Ipth Level ◽  
Ckd Stage ◽  
The Relationship

Introduction: Diabetes mellitus (DM) is one of the leading causes of chronic kidney disease (CKD). Management of chronic kidney disease-mineral and bone disorder (CKD-MBD) is an integral component of CKD management; serum intact parathyroid hormone (iPTH) level is the key target. This study was designed to evaluate the relationship between glycated haemoglobin (HbAlc) and iPTH in diabetic CKD stages 3-5 patients not yet on dialysis.Methods: This cross-sectional study was conducted in BIRDEM General Hospital, Dhaka, Bangladesh from January 2013 to December 2014. Diabetic patients suffering from CKD stages 3-5, who were not on dialysis, were consecutively and purposively included in this study. Along with base-line characteristics, clinical and laboratory data including HbAlc and iPTH levels were recorded for all patients. Data were analyzed by using SPSS version 20.0 and Pearson’s correlation test was applied to evaluate the relationship between HbAlc and iPTH.Results: Total patients were 306, including 166 (54.2%) males. Mean age was 56.5±11.3 years. Mean duration of DM and CKD were 12.8±7.6 and 2.9±1.7 years respectively. Among the study population, 49 (16.0%) were in CKD stage 3, 90 (29.4%) in CKD stage 4 and rest 167 (54.6%) in CKD stage 5. Mean HbAlc (%), serum creatinine (mg/dl), urea (mg/dl), calcium (mg/dl), phosphate (mg/dl), alkaline phosphatase (U/L) and iPTH (pg/ml) were 7.77±2.14, 6.8±3.0, 141.1±75.7, 8.1±1.2, 5.2±1.9,164.1±135.3 and 229.7±151.2 respectively. Mean HbAlc (%) and iPTH (pg/ml) in CKD stages 3, 4 and 5 were 8.36±1.59 and 171.7±127.9, 7.99±1.92 and 179.5±131.4, and 7.77±2.14 and 273.8±119.2 respectively. On correlation analysis, HbAlc had a significant negative correlation with iPTH (r=-0.002).Conclusion: The results of current study showed that most diabetic CKD stages 3-5 predialysis patients had poor glycaemic control and HbAlc had negative correlation with iPTH. As iPTH level is influenced by presence and control of DM, the targets of iPTH in CKD stages 3-5 in general, as recommended in existing guidelines, may not be appropriate in diabetic CKD patients and this issue merits further investigation.Birdem Med J 2017; 7(2): 110-113

Sign in / Sign up

Export Citation Format

Share Document